女性不孕症 中国就医指南

Female infertility is defined as the inability to achieve a clinical pregnancy after 12 months or more of regular, unprotected sexual intercourse. In women aged 35 years and older, evaluation is recommended after just 6 months due to age-related declines in ovarian reserve and oocyte quality. The condition is not a single disease but a heterogeneous syndrome with multifactorial origins—including ovulatory disorders (e.g., PCOS, hypothalamic amenorrhea, premature ovarian insufficiency), tubal factor infertility (often from pelvic inflammatory disease or endometriosis-related adhesions), uterine abnormalities (e.g., fibroids, adenomyosis, congenital malformations), cervical/mucosal factors, and unexplained causes accounting for ~15–30% of cases. Pathogenesis involves complex interplay among endocrine dysregulation, chronic inflammation, oxidative stress, genetic and epigenetic factors, and environmental exposures. Globally, infertility affects approximately 10–15% of reproductive-age couples, with female factors contributing to ~40–50% of cases—either solely or in combination with male factor infertility. Prevalence rises significantly with advancing maternal age: women aged 35–39 have ~25% lower natural conception rates per cycle compared to those under 30; by age 40, live birth rates per IVF cycle drop below 15%. Key modifiable risk factors include obesity (BMI ≥30), underweight (BMI <18.5), smoking, excessive alcohol intake, recreational drug use, prolonged stress, sedentary lifestyle, and exposure to endocrine-disrupting chemicals (e.g., BPA, phthalates). Non-modifiable risks include advanced maternal age, prior pelvic surgery, history of chlamydia or gonorrhea, endometriosis, autoimmune conditions (e.g., thyroiditis, celiac disease), and family history of early menopause. Psychologically, female infertility imposes profound burdens: high rates of anxiety (up to 45%), depression (30–40%), marital strain, social isolation, diminished self-worth, and occupational disruption. Many patients report stigma, especially in cultures emphasizing motherhood as central to female identity. Financial toxicity from repeated diagnostic testing and treatment cycles further exacerbates distress. Quality-of-life studies consistently show significant impairments across physical, emotional, social, and sexual domains—comparable to those seen in chronic conditions like cancer or diabetes. Early, patient-centered, multidisciplinary care—including reproductive endocrinology, psychology, nutrition, and complementary therapies—is essential to mitigate both biological and psychosocial morbidity.

# 女性不孕症治疗方案与费用明细（生殖医学科）

一、非手术/保守治疗方案

适用人群：排卵障碍、轻度PCOS、黄体功能不足、不明原因不孕（输卵管通畅、男方正常）

• •促排卵药物治疗（克罗米芬/来曲唑/尿促性素）：含3–6周期监测（B超+性激素6项），1,800–4,200元/周期
• •生活方式干预+中药调理（含中医辨证、针灸、基础代谢评估）：2,600–5,500元/3个月疗程
• •宫腔内人工授精（IUI）：含精液优化、排卵监测、操作及术后黄体支持，3,200–4,800元/周期

二、手术/微创介入方案

适用人群：输卵管粘连/积水、中重度子宫内膜异位症、宫腔粘连、多囊卵巢综合征（药物抵抗）

• •腹腔镜联合宫腔镜手术（输卵管整形+盆腔松解+宫腔粘连分离）：术前检查（传染病八项、心电图、胸片、阴道分泌物）1,900–2,400元；手术+麻醉+住院（5–7天）18,500–32,000元
• •卵巢打孔术（LOD）：单侧/双侧，含术前评估及术后管理，12,000–16,800元

三、辅助生殖技术（ART）核心方案

适用人群：输卵管阻塞、重度内异症、卵巢储备下降、反复IUI失败

• •常规IVF-ET：含长方案/拮抗剂方案、取卵、胚胎培养、鲜胚移植，32,000–45,000元/周期
• •冻胚移植（FET）：含内膜准备、解冻、移植及黄体支持，12,000–16,500元/周期

四、特殊复杂情况方案

• •卵巢低反应/高龄（≥40岁）：微刺激+自然周期IVF，加用生长激素预处理，48,000–65,000元/周期
• •反复种植失败（RIF）：ERA检测+免疫调节（如泼尼松/羟氯喹）+宫腔灌注，52,000–78,000元/周期

方案快速选择指南

✅ 预算≤3万元/年：优先IUI（2–3周期）+促排卵； ✅ 3–8万元/年+中重度病变：腹腔镜手术后衔接IVF； ✅ ≥8万元+高龄/RIF：直接启动个体化IVF+ERA/免疫干预。